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Abstract
Background: Recent exercise guidelines for people with multiple sclerosis (MS) recommend a minimum of 30 min
moderate intensity aerobic exercise and resistance exercise twice per week. This trial compared the secondary
outcomes of a combined 10-week guideline based intervention and a Social Cognitive Theory (SCT) education
programme with the same exercise intervention involving an attention control education.
Methods: Physically inactive people with MS, scoring 0–3 on Patient Determined Disease Steps Scale, with no
MS relapse or change in MS medication, were randomised to 10-week exercise plus SCT education or exercise plus
attention control education conditions. Outcomes included fatigue, depression, anxiety, strength, physical activity,
SCT constructs and impact of MS and were measured by a blinded assessor pre and post-intervention and 3 and
6 month follow up.
Results: One hundred and seventy-four expressed interest, 92 were eligible and 65 enrolled. Using linear mixed
effects models, the differences between groups on all secondary measures post-intervention and at follow-up were not
significant. Post-hoc, exploratory, within group analysis identified improvements in both groups post intervention in
fatigue (mean Δ(95% CI) SCT -4.99(−9.87, −0.21), p = 0.04, Control −7.68(−12.13, −3.23), p = 0.00), strength
(SCT -1.51(−2.41, −0.60), p < 0.01, Control −1.55(−2.30, −0.79), p < 0.01), physical activity (SCT 9.85(5.45, 14.23),
p < 0.01, Control 12.92(4.69, 20.89), goal setting (SCT 7.30(4.19, 10.4), p < 0.01, Control 5.96(2.92, 9.01), p < 0.01) and
exercise planning (SCT 5.88(3.37, 8.39), p < 0.01, Control 3.76(1.27, 6.25), p < 0.01) that were maintained above baseline
at 3 and 6 month follow up (all p < 0.05). Only the SCT group improved at 3 and 6 month follow up in physical impact
of MS(−4.45(−8.68, −0.22), −4.12(−8.25, 0.01), anxiety(−1.76(−3.20, −0.31), −1.99(−3.28, −0.71), depression(−1.51(−2.89, −0.
13), −1.02(−2.05, 0.01)) and cognition(5.04(2.51, 7.57), 3.05(0.81, 5.28), with a medium effect for cognition and fitness
(Hedges’ g 0.75(0.24, 1.25), 0.51(0.01, 1.00) at 3 month follow up.
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Conclusions: There were no statistically significant differences between groups for the secondary outcomes once age,
gender, time since diagnosis and type of MS were accounted for. However, within the SCT group only there were
improvements in anxiety, depression, cognition and physical impact of MS. Exercising at the minimum guideline amount
has a positive effect on fatigue, strength and PA that is sustained at 3 and 6 months following the cessation of the
program.
Trial registration: ClinicalTrials.gov, NCT02301442, retrospectively registered on November 13th 2014.
Keywords: Multiple sclerosis, Exercise, Fatigue, Cognition, Behaviour change techniques, Social cognitive theory,
Randomised controlled trial
Background
Multiple sclerosis (MS) is a chronic and often progressive
condition affecting the central nervous system. MS has
many consequences, including impaired strength, fitness,
mood, fatigue and cognition, along with limitations of
activities such as walking that impact on quality of life.
Available evidence supports the beneficial effects of exer-
cise on fatigue [1, 2], depression [3] fitness [4], walking
mobility [5, 6], in addition to quality of life [7]. Indeed, this
evidence has led to the development of the MS Exercise
guideline [8, 9] which recommends moderate intensity
aerobic exercise for 30 min and resistance training involv-
ing major muscle groups twice weekly.
We are not aware of a single trial that has actually docu-
mented the benefits of the exercise guidelines in MS. Of
further concern, there are few studies in the MS exercise
literature that have evaluated the long-term benefits of
exercise interventions, and the results are mixed. For
example, we reported positive improvements from a com-
bined aerobic and resistance exercise programme in the
community [10]; however, the improvements generally
were not maintained 12 weeks post-intervention [11], sug-
gesting that additional measures are required to enable
sustained increases in physical activity behaviour among
PwMS. This need to foster long-term exercise participa-
tion is not unique to PwMS and authors have highlighted
the need to include theory-based behaviour change inter-
ventions [12]. Social cognitive theory has been extensively
investigated among PwMS, and exercise self-efficacy and
goal setting are consistently associated with [13] and pre-
dictive of [14] physical activity behaviour. Indeed a recent
meta-analysis demonstrated significant associations of
these constructs and outcome expectancies with physical
activity [15].
We have conducted a series of clinical trials (i.e.,
Phase I and II) with relatively small samples for
examining the efficacy of an Internet-delivered behav-
ioural intervention based on social cognitive theory
(SCT) for increasing physical activity among ambula-
tory persons with MS [16–19]. Our most recent trial
included the website and one-one-one video coaching
and demonstrated moderate to large improvements in
minutes/day of moderate/vigorous physical activity, en-
durance walking performance, information processing
speed, symptoms of fatigue, depression, anxiety, and pain,
and quality of life (QOL) over a six-month period [20].
Collectively, such data support the efficacy of the behav-
ioural intervention for increasing and sustaining physical
activity in PwMS and possibly improving walking, cogni-
tion, symptoms, and QOL outcomes.
The Step it Up study [21] combined the collective
knowledge and expertise gained from the Irish community
exercise programme with the U.S. online intervention.
The 10-week programme firstly aimed to enable inactive
PwMS to reach the recently published aerobic and resist-
ance exercise guidelines. We further investigated how
embedding this exercise programme in a structured SCT-
based education intervention compared to an attention-
control education intervention. The current paper reports
the results for the secondary outcomes of MS symptoms,
physical activity, and SCT constructs. The primary out-
come and feasibility metrics, presented elsewhere (Hayes
et al. in press) demonstrated that both groups improved
significantly in the primary outcome, the six minute walk
test (6MWT), and this improvement was maintained at
6 month follow-up. An exploratory analysis of those with
three of four assessments demonstrated that the SCT
group had a ~ 40 m greater improvement in 6MWT than
the control group post-intervention and at 6-month
follow up (p = 0.04 for both).
Methods
Design
This was a multicentre, double blind, randomised con-
trolled trial (RCT).
Setting and participants
Participants were recruited through the MS Society of
Ireland, and via neurology clinics in three urban loca-
tions in the Republic of Ireland. Details of the recruit-
ment process are further detailed in the protocol paper
[21]. Inclusion criteria were: (1) physician-confirmed
formal diagnosis of MS, (2) aged 18 years or more, (3)
Patient Determined Disease Steps (PDDS) scale score of
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0–3, (4) a sedentary lifestyle (<30 min of moderate to
strenuous exercise one day or more per week over the
last six months) and (5) willing to give written in-
formed consent. Exclusion criteria were: (1) pregnancy,
(2) MS relapse in the previous 12 weeks and (3)
changes to MS medication or steroid treatment in the
previous 12 weeks. Participants were sent the consent
form in advance of the baseline assessment, and written
consent was obtained in person by a blinded assessor.
Randomisation and blinding
Participants were randomly allocated into the exercise
plus SCT-based intervention or the exercise plus attention
control education intervention. Random allocation proce-
dures have been previously outlined [21] and were ad-
hered to. JN generated the random allocation sequence,
SH enrolled participants, and SC assigned participants to
interventions. The outcome assessor (SH) was blind to al-
location throughout the study as were the statisticians
(CS, JN). All participants were informed that the study
aimed to examine the effect of combining exercise and
education, and therefore were blinded regarding group
allocation.
Screening questionnaire
Potential participants were screened for eligibility for
this study using a questionnaire that included the Patient
Determined Disease Steps (PDDS) scale [22], confirm-
ation from participant of MS diagnosis and questions re-
garding PA levels that have been detailed elsewhere [21].
Outcomes
Outcome measures were conducted pre-intervention
post-intervention and at 3 and 6 month follow-up.
At baseline, participants provided demographic details
and a researcher formally trained in the use of the
Expanded Disability Status Scale (EDSS [23]) (SH) ad-
ministered the EDSS to all participants at baseline. MS
diagnosis according to the McDonald or Poser criteria
was confirmed in writing from the participant’s con-
sultant neurologist.
The SenseWear Arm band (SWA) provided an objective
estimate of PA [24] using both mean daily step count and
mean daily energy expenditure estimates over a 7-day
period. The 5 times sit to stand test (5xSTS) [25], the
Modified Canadian Aerobic Fitness Test (mCAFT) [26]
and the Godin Health Index of the Godin Leisure-Time
Exercise Questionnaire (GLTEQ) [27] measured lower ex-
tremity muscle strength, aerobic capacity and PA behav-
iour, respectively. The Hospital Anxiety and Depression
Scale (HADS) [28], Symbol Digit Modalities Test (SDMT)
[29], Multiple Sclerosis Impact Scale 29 (MSIS-29) [30],
and Modified Fatigue Impact Scale (MFIS) [31] measured
depression, anxiety, cognitive processing speed, impact of
MS and fatigue, respectively. Five questionnaires were
implemented to measure SCT domains. These included
the Exercise Self-Efficacy Scale (EXSE) [32], Exercise Goal
Setting (EGS) scale [33], Multidimensional Outcomes
Expectations for Exercise Scale (MOEES) [34], Social
Provisions Scale (SPS) [35], and Exercise Benefits and
Barriers questionnaire [36]. These measures and associ-
ated psychometric properties have been described in the
trial protocol [21].
Interventions
The exercise intervention was common to both groups
and was delivered by physiotherapists. The aim of the ex-
ercise component was to progressively increase the inten-
sity of both aerobic and strengthening exercise to enable
the participants to reach the published exercise guidelines
for people with mild-to-moderate MS [37], and has been
previously described in detail [21]. Over the 10-week
programme participants attended the group exercise class
on six occasions, supplemented with a telephone coaching
call in the weeks without classes (intervention weeks 4, 6,
7 and 9). After each of the group exercise classes the
attention control group received an education session
about topics unrelated to PA behaviour, e.g. diet, vita-
min D, sleep, temperature and hydration, and immuni-
sations and vaccinations. The exercise plus SCT-based
intervention group received a similar duration of educa-
tion based on the principles of SCT for health behaviour
change, namely: self-efficacy, outcome expectations, goal-
setting, barriers and benefits and has been previously
described [21].
Analysis
The study was powered for the primary outcome, 6MWT
and consistent with data from a large international study
[38], it was assumed that the effect of the intervention
would yield an average improvement in 6MWT distance
of 36 m with an estimated standard deviation of 48.2 m.
In order to have 80% power (at the 5% significance level)
to detect such a difference in mean improvement in
6MWT over the study period between groups, a sample
of size 62 randomised equally to two arms (i.e. 31 per
arm) was needed.
Suitable numerical statistics and graphical summaries
were used to describe characteristics of the sample at
baseline and to assess the validity of any distributional
assumptions needed for the formal analysis. All tests of
significance were two-sided and conducted at an
alpha = 0.05 level of statistical significance.
The statistical modelling compared differences in the
longitudinal response variables between the two interven-
tion arms at each of the three post-intervention follow-
ups while correcting for the baseline measurements for
each participant. A linear mixed model for a continuous
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response over time due to the two interventions, whilst
adjusting for participant-specific covariates and factors;
namely the response of interest at baseline, age, gender,
time since diagnosis and MS type (i.e. benign, primary
progressive and relapsing-remitting) was developed.
Treatment and time (and their interaction) were specified
as fixed effects, centre (three levels) and participant
(nested in centre) as random effects in order to account
for homogeneity within centre and within participant cor-
relation over time. Initially a model containing the main
effects of the treatment, time and a treatment-by-time
interaction was specified in order to test whether there is
evidence that the treatment effects varies over time. If the
interaction was deemed unnecessary (using a likelihood
ratio test) the model was refitted excluding the interaction
term, so the treatment effect was then constant over time.
All analyses were carried out using all available measure-
ments. All models were fitted in R 3.2.0 using the lme4
and lmerTest packages. Model diagnostics involved suit-
able plots of the residuals.
Given increased calls across the literature to move
beyond null-hypothesis significance testing in favour of
effect sizes and confidence intervals [39] we also quanti-
fied and compared the magnitude of change in secondary
outcomes using Hedges’ g effect sizes and associated 95%
confidence intervals (95%CI) using Cohen’s conventions
for effect sizes (0.2 small, 0.5 moderate, 0.8 large). For
each outcome measure, the mean baseline to post inter-
vention and 3 and 6 month change for the control condi-
tion was subtracted from the mean baseline to post
intervention and 3 and 6 month change for the interven-
tion condition and divided by the pooled baseline standard
deviation [40]. Effect sizes were calculated such that
greater improvements in outcomes in the intervention
group compared to the control group resulted in positive
effect sizes.
Fig. 1 CONSORT Flow Diagram, DNA: did not attend
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An exploratory paired t-test between baseline post
intervention and 3- and 6- month follow-ups was also
conducted. This provides a summary of the effects of the
estimated treatment and control from the raw data. These
“unadjusted” results do not account for the patient covari-
ates and repeated measurements.
Results
One hundred and seventy-four PwMS contacted the trial
centre and were screened for inclusion over the phone be-
tween September 2013 and May 2014. Figure 1 illustrates
the flow through the trial, including reasons for loss to
follow-up and discontinuation of intervention. We ran-
domised 92 individual participants and waited for 6
participants in a region to run a group before baseline
assessment. While waiting for others to be randomised,
27 people became ineligible or declined to participate.
One participant was not treated as randomised (two ac-
quaintances had been randomised to the other group
and the participant wanted to exercise with them).
Sixty-five participants were assessed at baseline and
commenced the intervention (intervention group
n = 33, control group n = 32). Baseline demographics
are presented in Table 1; the groups were similar at
baseline. Feasibility, fidelity and adherence metrics are
published elsewhere (Hayes et al. in press).
The raw data at each time point is presented in Table
2. Linear mixed effects models showed no statistically
significant differences between the SCT and control
groups for any secondary outcome at post intervention
and at 3 and 6 month follow up assessment points
(Table 2). Hedges’ g effect sizes and associated 95% CIs
are also presented for each group in Table 3. At three
month follow up, compared to the control group, the ex-
ercise and SCT education resulted in statistically signifi-
cant moderate-to-large improvements in cognitive
processing speed (SDMT: g = 0.75, 95% CI: 0.24, 1.25)
and aerobic capacity (mCAFT: g = 0.51, 95% CI: 0.01,
1.00). Though not statistically significant, compared to
control post intervention, the SCT group had small-to-
moderate improvements in the perceived psychological
impact of MS (g = 0.25), anxiety symptoms (g = 0.34),
estimated energy expenditure (g = 0.39), exercise plan-
ning (g = 0.34), and social support (g = 0.40). Compared
to control at three month follow-up, the SCT group had
nonsignificant, small-to-moderate improvements in the
perceived psychological impact of MS (g = 0.34), anxiety
(g = 0.37) and depressive (g = 0.20) symptoms, lower
extremity muscle strength (g = 0.41), estimated energy
expenditure (g = 0.40), exercise planning (g = 0.31), exer-
cise self-efficacy (g = 0.33), and social support (g = 0.49).
At six month follow-up, compared to control the inter-
vention showed nonsignificant small-to-moderate im-
provements in anxiety (g = 0.17) and depressive
(g = 0.23) symptoms, cognitive processing speed
(g = 0.15), lower extremity muscle strength (g = 0.49),
aerobic capacity (g = 0.34), exercise planning (g = 0.17),
exercise self-efficacy (g = 0.28), and social support
(g = 0.45).
Within-group outcome changes, including the un-
adjusted, unstandardized mean changes from baseline, as-
sociated 95%CIs, and paired t-test results for both groups,
are presented in Table 4. Both groups demonstrated
significant improvements from baseline following the 10-
week intervention in the perceived impact of fatigue
(MFIS), lower extremity muscle strength (5xSTS), self-
reported PA (Godin Health Index), exercise goal setting,
and exercise planning that are maintained above baseline
at three and six month follow-up. Only the SCT group
had significant improvements in perceived physical impact
of MS (MSIS-29 physical), anxiety (HADS-A) and depres-
sive (HADS-D) symptoms, and cognitive processing speed
(SDMT) at three and six month follow-up. There was no
significant change in objectively-measured PA using the
outputs of steps and energy expenditure, and no signifi-
cant change in exercise self-efficacy in either group across
time points.
Discussion
This paper presents the secondary outcome results
from an intervention designed to enable inactive people
with MS to reach the minimum recommendation of the
MS Exercise Guidelines and further compared the effect
of a structured SCT-based education to an attention-
control education intervention. Null hypothesis testing
Table 1 Clinical baseline characteristics of those receiving exercise
plus SCT (SCT) and exercise plus control education (CON)
SCT (n = 33) CON (n = 32)
MS type
Benign 3 1
Primary progressive 1 0
Relapsing-remitting 27 27
Secondary progressive 0 1
Not reported 2 3
EDSS (mean, SD) 3.3 (0.7) 3.3 (0.7)
Years since diagnosis (mean, SD) 6.7 (5.7) 7.0 (6.1)
Centre (n)s
Cork 10 9
Galway 8 10
Limerick 15 13
Age (years) 43.3 (9.9) 41.9 (9.3)
Gender (n)
Male 4 6
Female 29 26
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demonstrated no statistically significant between-group
differences for any secondary outcome over time. How-
ever, examination of the magnitude of change quantified
by Hedges’ g effect sizes illustrated potentially important
differences between exercise plus SCT compared to the at-
tention control condition, including significant moderate-
to-large improvements in cognitive processing speed and
aerobic capacity at three month follow-up. Additionally,
though not statistically significant, compared to the
attention-control condition, exercise plus SCT resulted
in small-to-moderate improvements of ¼ to ½ standard
deviation in anxiety and depressive symptoms, the per-
ceived psychological impact of MS, cognitive processing
speed, aerobic capacity, estimated energy expenditure,
exercise planning, and social support, and the magni-
tude of many of these improvements persisted at 24-
and 36-week follow-up. The magnitude of improve-
ments in these outcomes is consistent with previous
reports of the positive effects of exercise training on
symptoms among PwMS, including fatigue [1], anxiety
[41], depression [42, 43], quality of life [7, 44], and mo-
bility [5], and highlights the potential additive benefit of
combined SCT-based education and exercise training.
The finding that both groups improved in strength
and physical activity is not surprising given the content
of the intervention. Participants completed twice weekly re-
sistance exercise and moderate intensity walking exercise.
The changes in lower extremity muscle strength 6 months
post intervention, measured with the 5xSTS test, are in line
broadly with previously reported changes using that meas-
ure [45], providing support for the fidelity of the current
intervention to enhance strength. The Health Index score
of the GLTEQ also increased in both groups, confirming
the exercise log data which indicated that SCT and the
CON group groups completed an average of 33.2 of 44
available sessions (75.5%) and 32.0 sessions (72.6%), re-
spectively (Hayes et al. in press). Of note, the objective
measure of PA, mean steps/day and mean energy expend-
iture/day did not change in line with the positive effects on
walking mobility and the increase in PA reported in the
exercise logs and the GLTEQ Health Index. This may be
due to reduced non-exercise physical activity, such that par-
ticipants reduced leisure, transport and occupational PA in
order to engage in exercise training, thereby maintaining,
or even decreasing, their overall PA levels. There has been
some support in the literature for initial decreases in non-
exercise physical activity when beginning an exercise train-
ing intervention, though the available evidence suggests
that decreased activity dissipates with continued training
[46]. It is also possible that the arm worn accelerometer did
not capture the changes in PA or that an alternative output,
such as increased mild/moderate PA specifically or a reduc-
tion in sedentary behaviour, may capture the changes due
to the intervention.
Importantly, the results of within-group changes con-
firmed the positive effect of exercise on fatigue for people
with MS [1, 2]. The included sample of PwMS started with
scores on the MFIS greater than 38 [47], indicative of clin-
ically meaningful fatigue, and both groups improved,
reporting scores below 38 at three and 6 month follow up.
To the authors’ knowledge, this is the first study to con-
firm that exercising at the minimum recommendations of
the Canadian MS Exercise guideline [9] has a positive
effect on fatigue for inactive people with MS with mild-
moderate disability.
Both groups also improved in exercise goal setting and
planning and these improvements were maintained at
both follow-up assessments. This was expected in the
SCT group because the structured education interven-
tion specifically addressed these and other SCT domains.
The improvement in the control group was unexpected
as they engaged in didactic education on topics unre-
lated to exercise. On reflection, in our efforts to docu-
ment adherence and fidelity to the intervention, we
inadvertently provided the control group with several
physical activity behaviour change techniques (BCT’s)
[12]. This involved exercising in a group setting, advice
on the guideline amount and its benefits, recording
exercise in a log, seeing personal improvements and
monitoring step count on a pedometer. Participants
further reported in our qualitative data that knowing
they were going to be assessed at 3- and 6-months
further served as a motivator to keep exercising. These,
somewhat “simple”, BCT’s warrant consideration for
inclusion in interventions that aim to enable long term
exercise behaviour and its benefits though we note that
there was a greater improvement in the SCT group for
the primary outcome of walking endurance seen in a per
protocol analysis (Hayes et al. in press). Adding a
booster session with both assessment and intervention
in the follow up periods may further maintain exercise
behaviour and its associated outcomes and is in line with
a recent systematic review [48] and reports from partici-
pants in this study.
Interestingly exercise self efficacy did not change
neither did outcome expectancies or exercise benefits.
Notably, compared to the control condition, exercise plus
SCT resulted in small, nonsignificant improvements in
self-efficacy and exercise plus SCT also resulted in near
half-standard deviation improvements in social support,
measured with the Social Provisions Scale, at all time
points. Though the objective of the current study was not
to examine plausible mediators of the effects of exercise
plus SCT on outcomes, given previous evidence of the
potential intermediary role of social support in the effects
of physical activity and exercise among PwMS [49], the
ability of exercise to concurrently improve social support
and symptoms may be particularly important.
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Interestingly only the SCT group demonstrated im-
provements in physical impact of MS, anxiety, depres-
sion and cognition. Compared to the attention-control
condition, the exercise plus SCT group showed small-
to-moderate improvements in anxiety and depressive
symptoms, the perceived psychological impact of MS,
and cognitive processing speed. These findings warrant
further focused examination but may be due in part to
the greater change in walking mobility seen in the exer-
cise plus SCT group (Hayes et al. in press). Both groups
improved significantly in six minute walk test (6MWT)
distance after treatment and at 3- and 6-month follow-
up, and using intention-to-treat analysis the SCT group
demonstrated 22.70 m, 11.80 m and 27.42 m greater
improvements in this measure. Data suggest that a
21 m change is clinically meaningful to participants,
supporting the hypothesis that the SCT group had more
meaningful changes in 6MWT distance at 3- and 6-
month follow-up that may have resulted in reduced
physical impact of MS. More of the SCT group reached
the guideline and they reported completing more ses-
sions. This increased “total exercise dose” and the
resulting change in depression is supported by our re-
cent systematic review and meta-regression analysis
[42], which found increased frequency of exercise was
associated with greater reductions of depression. There
is limited specific information on the dose/response re-
lationship of exercise for MS and this warrants consid-
eration in trials designed specifically to address this
question.
Strengths and limitations
The main strength of this study is that we purposely
recruited inactive people with MS and engaged them in
a 10-week exercise and education programme with the
aim of enabling long-term physical activity engagement
and its associated benefits. A weakness is that we did
not power the study for these secondary outcomes;
nonetheless, the preliminary findings presented in the
current paper, particularly the magnitude of improve-
ments in fatigue, anxiety and depressive symptoms, the
perceived impact of MS, strength and aerobic capacity,
and cognitive processing speed, will inform future trials
and targeted analyses of these important factors. A fur-
ther strength is that we measured a broad range of MS
symptoms, and reported the effect of the resistance and
aerobic exercise programme on strength, fitness, and
subjectively and objectively measured PA. A limitation is
that the measures of objective PA and fitness did not
change and a more direct measure of fitness, such as cycle
ergometry to determine VO2 max, is recommended [50].
Participants reported some dissatisfaction with the SWA
arm band; therefore, alternative tools for objectively meas-
uring PA among PwMS are warranted. A further strength
is that we used exercise logs to capture intensity of aerobic
exercise using steps from a pedometer, but a limitation is
that we did not record heart rate and this is recommended
in future trials.
Conclusion
This paper presents data to suggest that enabling
inactive people with mild-moderate disability due to MS
to exercise at the minimum suggested by the exercise
guideline results in a range of benefits. Improvements in
fatigue, strength, goal setting and planning were seen in
both the structured SCT and attention control groups
and were maintained at 3 and 6 month follow up. The
similar responses in both groups for these secondary
outcomes can be explained as they both had the same
exercise intervention and by the inadvertent inclusion of
several behaviour change techniques for the control group
through our adherence logging and trial structure.
The results of this pilot trial for the secondary outcome
measures suggest that the SCT group had greater im-
provements in cognitive processing and aerobic capacity
at 3 month follow up. This paper further presents prelim-
inary evidence for improvements in physical impact of
MS, anxiety, depression and cognition in the exercise plus
SCT group alone. This may in part be due to the greater
improvements in walking mobility reported elsewhere or
due to the content of the education element and therefore
further testing of the intervention model is warranted.
These findings, in combination with the effects for the
primary outcome measure, warrant progression to a de-
finitive RCTand suggest the importance of studies directly
investigating the dose-response relationship with focal
outcomes.
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